Mode
Text Size
Log in / Sign up

HFNC shows significantly lower adverse event rates than CPAP in children with bronchiolitisHigh Flow Nasal Cannula Shows Fewer Side Effects for Bronchiolitis

AI-generated summary of the cited source, checked by automated accuracy review. How we work

Key Takeaway
Note that HFNC is associated with significantly fewer adverse events than CPAP in children with bronchiolitis.

This meta-analysis evaluated 10 RCTs involving 965 children with bronchiolitis to compare high-flow nasal cannula (HFNC) and continuous positive airway pressure (CPAP). The primary outcome of treatment failure showed no significant difference between the two interventions (RR: 0.80; 95% CI: 0.50 to 1.29, p=0.37). While certain subgroups, such as pediatric wards with mean age over 3 months and weight over 6 kg, showed a lower risk of treatment failure for HFNC, the overall result was not statistically significant.

Regarding secondary outcomes, no significant difference was found between HFNC and CPAP for invasive mechanical ventilation (RR: 0.88; 95% CI: 0.61 to 1.29, p=0.51). However, a significant safety benefit was observed, with HFNC associated with a significantly lower incidence of adverse events compared to CPAP (RR: 0.35; 95% CI: 0.22 to 0.57).

The evidence for treatment failure is characterized as moderate certainty, while the evidence for invasive mechanical ventilation is low certainty. No specific limitations were reported by the authors.

How this fits prior evidence

This meta-analysis addresses a gap regarding the comparison of HFNC and CPAP specifically. It extends prior coverage showing that HFNC reduces treatment failure and PICU stay in pediatric bronchiolitis compared to LFNC, but provides new comparative safety data against CPAP. Specifically, it confirms that while treatment failure rates may not differ significantly between HFNC and CPAP, HFNC is associated with a significantly lower incidence of adverse events (RR: 0.35).

This meta-analysis looked at 965 children diagnosed with bronchiolitis to compare two types of breathing support: high-flow nasal cannula (HFNC) and continuous positive airway pressure (CPAP). The study aimed to see which method was more effective at preventing treatment failure and reducing the need for invasive mechanical ventilation.

The results showed no significant difference between HFNC and CPAP in terms of overall treatment failure or the need for invasive mechanical ventilation. However, a subgroup analysis suggested that HFNC might have a lower risk of treatment failure specifically in certain groups, such as children over 3 months old weighing more than 6 kilograms.

One notable finding was regarding safety. The study found that children using high-flow nasal cannula had significantly fewer adverse events compared to those using CPAP. Because the evidence for some outcomes is limited or of low certainty, these findings should be discussed with a doctor to determine the best care plan for a child.

What this means for you:
HFNC and CPAP show similar success rates for bronchiolitis, but HFNC is linked to fewer side effects.

Common questions

Is it safer to use a high-flow nasal cannula for my child?

The study found that high-flow nasal cannula (HFNC) was associated with significantly fewer adverse events compared to CPAP. While both methods showed similar rates of treatment failure and invasive ventilation, the lower rate of side effects makes HFNC a notable option for managing bronchiolitis in children.

How does high-flow nasal cannula compare to CPAP for treatment success?

The analysis of 10 trials involving 965 children showed no significant difference between HFNC and CPAP regarding overall treatment failure or the need for invasive mechanical ventilation. Some specific subgroups, like those over 3 months old, may see lower risk with HFNC, but results are not consistent across all ages.

What is bronchiolitis and how is it treated?

Bronchiolitis is a common lung infection in children. This study specifically compared two ways to provide breathing support: high-flow nasal cannula (HFNC) and continuous positive airway pressure (CPAP). You should speak with your doctor to determine which treatment is best for your child's specific needs.

Study Details

Study typeMeta analysis
EvidenceLevel 1
PublishedAug 2026
View Original Abstract ↓
BackgroundHigh-flow nasal cannula (HFNC) and continuous positive airway pressure (CPAP) are increasingly used for noninvasive respiratory support in children with bronchiolitis, but their comparative efficacy and safety remain uncertain. This meta-analysis aimed to compare HFNC and CPAP in children with bronchiolitis based on evidence from randomized controlled trials (RCTs).MethodsPubMed, Cochrane Library, Embase, Web of Science, Wanfang, and CNKI were systematically searched for RCTs comparing HFNC and CPAP in children with bronchiolitis. The primary outcome was treatment failure. Secondary outcomes included invasive mechanical ventilation (MV) and adverse events (AEs). Risk ratios (RRs) with 95% confidence intervals (CIs) were pooled using a random-effects model.ResultsTen RCTs involving 965 children were included. Overall, HFNC was not associated with a significantly different risk of treatment failure compared with CPAP (RR: 0.80, 95% CI: 0.50–1.29, p = 0.37; moderate-certainty evidence). Subgroup analyses suggested that HFNC was associated with a lower risk of treatment failure in children treated in pediatric wards, in studies with mean age >3 months, and in those with mean body weight >6 kg. The rate of invasive MV was also not significantly different between groups (RR: 0.88, 95% CI: 0.61–1.29, p = 0.51; low-certainty evidence). Howevnker, HFNC was associated with a significantly lower incidence of AEs compared with CPAP (RR: 0.35, 95% CI: 0.22–0.57, p 
Free Newsletter

Clinical research that matters. Delivered to your inbox.

Join thousands of clinicians and researchers. No spam, unsubscribe anytime.